Amgens GLP-1 agonist and GiPR antagonist MariTide:
Achieved 20% weight loss over 52 weeks in phase 2, in people with #obesity or overweight without T2 #diabetes.
Those with T2 diabetes achieved up to 17% weight loss.
Shares slid as analysts expected 25% weight loss!
Sky high expectations.
10 months ago